Skip to main content
. 2022 May 31;23:141. doi: 10.1186/s12931-022-02052-3

Table 1.

Baseline characteristics of study participants

Total (N = 489)
Age, years 67.3 ± 11.6
Male 309 (63.2)
Ethnicity, white 391 (81.0)
Smoking status
 Current smoker 287 (58.7)
 Ex-smoker 173 (35.4)
 Never smoker 29 (5.9)
 Asthma 119 (24.4)
 Cardiac comorbidities* 182 (37.3)
Lung function
 Post-bronchodilator FVC, L 2.8 ± 1.1
 Post-bronchodilator FVC, %predicted 77.6 ± 23.1
 Post-bronchodilator FEV1, L 1.5 ± 0.8
 Post-bronchodilator FEV1, %predicted 53.7 ± 23.8
 Post-bronchodilator FEV1/FVC 45.2 ± 24.8
IgG subclass deficiency
 IgG1 deficiency 9 (1.8)
 IgG2 deficiency 59 (12.1)
 IgG3 deficiency 21 (4.3)
 IgG4 deficiency 55 (11.3)
 1-year mortality 101 (20.7)

Data are presented as numbers (%) or mean ± SD

FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, IgG immunoglobulin G

*Cardiac comorbidities included a history of heart failure, myocardial infarction, stable coronary disease, or coronary artery bypass graft surgery